Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              ReAlta Life Sciences

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED KINGDOM United Kingdom

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              BE PHARMA 2020

              Participation Not Confirmed

              Update your events

              ReAlta Life Sciences Closes $14 Million Series A2 Financing to Support Transition into a Clinical Organization

              Contact the Supplier

              Lead Product(s): RLS-0071

              Therapeutic Area: Neurology Product Name: Undisclosed

              Highest Development Status: IND Enabling Product Type: Large molecule

              Partner/Sponsor/Collaborator: Children’s Research Holdings

              Deal Size: $14.0 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing April 21, 2020

              Details:

              Proceeds will fund advancement of programs addressing acute lung injury due to COVID-19 and severe birth asphyxia (HIE).

              ReAlta Life Sciences

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED KINGDOM United Kingdom

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              BE PHARMA 2020

              Participation Not Confirmed

              Update your events

              ReAlta Life Sciences Announces FDA Orphan Drug Designation for PIC1

              Contact the Supplier

              Lead Product(s): PIC1-dPEG24

              Therapeutic Area: Neurology Product Name: Undisclosed

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 06, 2020

              Details:

              PIC1 positioned as a novel pharmacological intervention to improve survival and cognitive outcomes for newborns affected by devastating disease.

              PharmaCompass__DigitalAd